Synthetic Peptides to Inhibit HIV Entry
Chang Yi Wang of United Biomedical, Inc. in the United States will develop and test synthetic peptide immunogens that mimic conserved sites used by HIV to gain entry to host T-cells. Mimicking the correct three-dimensional structure of these important proteins should generate antibody responses that block this initial step of HIV infection and neutralize the virus.